Short Interest in Briacell Therap (NASDAQ:BCTX) Rises By 108.0%

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totaling 472,347 shares, a growth of 108.0% from the April 15th total of 227,052 shares. Approximately 6.6% of the shares of the company are short sold. Based on an average daily volume of 182,536 shares, the short-interest ratio is currently 2.6 days.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research note on Monday, April 20th. Wall Street Zen raised shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Briacell Therap Price Performance

Briacell Therap stock traded down $1.03 during mid-day trading on Friday, reaching $3.02. The stock had a trading volume of 1,664,570 shares, compared to its average volume of 150,768. The company has a market capitalization of $21.90 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. The company has a 50-day moving average price of $4.14 and a two-hundred day moving average price of $6.28. Briacell Therap has a one year low of $2.98 and a one year high of $37.20.

Briacell Therap (NASDAQ:BCTX) last posted its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent SEC filing. Institutional investors own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.